A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages

Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense stroma and myeloid-rich microenvironment that confer resistance to immunotherapies. Previous studies demonstrated that disrupting the immune-stroma CXCR4-CXCL12 axis facilitates T cell recruitment and mobility to collaborate with anti...

Full description

Bibliographic Details

Published in:	OncoImmunology
Main Authors:	Katherine M. Bever, Sarah M. Shin, Jennifer N. Durham, Hanfei Qi, Alexei Hernandez, Erin M. Coyne, Nicole E. Gross, Soren Charmsaz, Jayalaxmi Suresh Babu, Diana Carolina Vargas Carvajal, Rohan Verma, Yanyi Sun, Zhehao Zhang, Xuan Yuan, Courtney D. Cannon, Sarah N. Hughes, Sarah Mitchell, Madeline Figlewski, James M. Leatherman, Hao Wang, Robert A. Anders, Elizabeth M. Jaffee, Dung T. Le, Won Jin Ho
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Subjects:	Cancer immunology checkpoint immunotherapy CXCL12 CXCR4 mass cytometry pancreatic cancer
Online Access:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2543614